DSGN - Design Therapeutics, Inc.
About Design Therapeutics, Inc. (https://www.designtx.com)
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Pratik Shah | Co-Founder, President, Chief Executive Officer, Principal Financial Officer & Executive Chairperson | 1970 | $790,000 USD |
| Sean Jeffries | Chief Operating Officer | 1980 | $698,000 USD |
| Chris Storgard | Chief Medical Officer | 1966 | $633,760 USD |
| Aseem Z. Ansari | Co-Founder & Scientific Advisor | – | – |
| Chengzhi Zhang | Chief Chemist | – | – |
| Doane Chilcoat | Chief Technology Officer | – | – |
| Jim Kerr | Chief of Manufacturing & Product Development | – | – |
| Julie D. Burgess | Chief Accounting Officer | – | – |
| Mustapha Parekh | General Counsel | – | – |
| Tadimeti S. Rao | Chief Scientific Officer | – | – |